Cancer biomarker discovery and validation

摘要: With the emergence of genomic profiling technologies and selective molecular targeted therapies, biomarkers play an increasingly important role in clinical management cancer patients. Single gene/protein or multi-gene "signature"-based assays have been introduced to measure specific pathway deregulations that guide therapeutic decision-making as predictive biomarkers. Genome-based prognostic are also available for several types potential incorporation into staging systems practice guidelines. However, there is still a large gap between initial biomarker discovery studies their translation due challenges process development. In this review we summarize steps development, highlight key issues successful validation implementation, overview representative examples oncology field. We discuss regulatory future perspectives era big data analysis precision medicine.